Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
Medtronic
Dow
Mallinckrodt

Last Updated: May 28, 2022

ANGIOMAX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Angiomax patents expire, and when can generic versions of Angiomax launch?

Angiomax is a drug marketed by Sandoz Inc and Maia Pharms Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ANGIOMAX is bivalirudin. There are fourteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.

Drug patent expirations by year for ANGIOMAX
Drug Prices for ANGIOMAX

See drug prices for ANGIOMAX

Recent Clinical Trials for ANGIOMAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Legacy Health SystemPhase 4
Pacific UniversityPhase 4
Qian GongPhase 2

See all ANGIOMAX clinical trials

Pharmacology for ANGIOMAX
Paragraph IV (Patent) Challenges for ANGIOMAX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ANGIOMAX For Injection bivalirudin 250 mg/vial 020873 1 2009-09-01

US Patents and Regulatory Information for ANGIOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Maia Pharms Inc ANGIOMAX RTU bivalirudin SOLUTION;INTRAVENOUS 211215-001 Jul 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ANGIOMAX

See the table below for patents covering ANGIOMAX around the world.

Country Patent Number Title Estimated Expiration
Canada 2079778 INHIBITEURS DE LA THROMBINE (INHIBITORS OF THROMBIN) See Plans and Pricing
Germany 69026715 See Plans and Pricing
Luxembourg 91119 See Plans and Pricing
Hong Kong 1001562 See Plans and Pricing
Australia 659828 See Plans and Pricing
South Korea 100199534 See Plans and Pricing
Singapore 79180 NOVEL INHIBITORS OF THROMBIN See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ANGIOMAX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0489070 22/2004 Austria See Plans and Pricing PRODUCT NAME: BIVALIRUDIN UND TRIFLUORACETAT DAVON; REGISTRATION NO/DATE: EU/1/04/289/001 20040920
0489070 CA 2004 00032 Denmark See Plans and Pricing
0489070 SPC/GB04/035 United Kingdom See Plans and Pricing PRODUCT NAME: H-(D-PHE)-PRO-ARG-PRO-(GLY)4-ASN-GLY-ASP-PHE-GLU-GLU-ILE-PRO-GLU-GLU-TYR-LEU-OH, OPTIONALLY IN THE FORM OF ITS PHARMACEUTICALLY ACCEPTABLE SALT (BIVALIRUDIN); REGISTERED: UK EU/1/04/289/001 20040920
0489070 300162 Netherlands See Plans and Pricing PRODUCT NAME: BIVALIRUDINE; FIRST REGISTRATION,DATE: EU/1/04/289/001, 20040920
0489070 91119 Luxembourg See Plans and Pricing 91119, EXPIRES: 20150817
0489070 C00489070/01 Switzerland See Plans and Pricing FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.